Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
New pharmaceutical compositions for oral use containing diclofenac together with alkali metal carbonates and bicarbonates and particular flavouring substances. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jan 2011 - 124 pages - $1,740
Jun 2008 - 175 pages - $3,835
Jul 2011 - 147 pages - $3,835
Jan 2007 - 126 pages - $2,495
Dec 2009 - 84 pages - $7,600
Oct 2011 - 92 pages - $3,835
Jan 2010 - $75
Jan 2011 - 231 pages - $3,835
Jun 2009 - 118 pages - $1,040
Nov 2009 - 830 pages - $1,040
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us